Blockade of PD-1/PD-L1 interaction with monoclonal antibodies reverses T cell exhaustion and prolongs survival benefit in patients with cancers such as melanoma, hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), gastric, and urothelial cancers [7,9,10,11]. The gene discussed is CD274; the disease is hepatocellular carcinoma.